Literature DB >> 30989632

Chemotherapy-Induced Cognitive Impairment Is Associated with Increased Inflammation and Oxidative Damage in the Hippocampus.

Ciara Bagnall-Moreau1,2, Sovira Chaudhry1, Kaliris Salas-Ramirez3, Tim Ahles4, Karen Hubbard5,6.   

Abstract

Increasing evidence indicates that chemotherapy results in long-term effects on cognitive dysfunction in some cancer survivors. While many studies have established the domains of cognition and corresponding regions in the brain most affected, little is revealed about the potential molecular mechanisms that mediate these adverse changes after treatment. The effects of chemotherapy on the brain are likely attributed to various mechanisms, including oxidative stress and immune dysregulation, features that are also reminiscent of cognitive aging. We have investigated the cognitive effects of a cocktail composed of doxorubicin and cyclophosphamide (AC-chemo) in a surgical ovariectomized rodent model. In this study, we address whether the levels of pro-inflammatory cytokines and oxidative stress-responsive gene markers are altered in the CNS of rats treated with systemic AC-chemo. We further evaluated the levels of nucleic acids modified by oxidative stress in the hippocampus using both immunohistochemical and Northern blotting techniques with a monoclonal antibody against 8-hydroxyguanosine (8-OHG) and 8-OHdG base lesions. We demonstrate that ERK 1/2 and JNK/SAPK signaling activities are elevated in the hippocampus of AC-chemo rats. The levels of pro-inflammatory, oxidative stress-responsive, and RNA/DNA damage markers were also higher in drug-injected animals relative to saline controls. The results indicate that the effects of AC chemotherapy are associated with oxidative damage and a global stress response in the hippocampus. These alterations in the molecular signature of the brain may underlie the processes that contribute to cognitive impairment after treatment.

Entities:  

Keywords:  Brain aging; Chemotherapy; Cognitive impairment; MAPK signaling; Neuro-inflammation; Oxidative damage

Year:  2019        PMID: 30989632      PMCID: PMC6728167          DOI: 10.1007/s12035-019-1589-z

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  24 in total

1.  Correlates of cognitive impairment in adult cancer survivors who have received chemotherapy and report cognitive problems.

Authors:  Shannon L Gutenkunst; Janette L Vardy; Haryana M Dhillon; Melanie L Bell
Journal:  Support Care Cancer       Date:  2020-07-14       Impact factor: 3.603

2.  Long-term changes of cognitive impairment among older breast cancer survivors.

Authors:  Juhua Luo; John T Schousboe; Kristine E Ensrud; Michael Hendryx
Journal:  J Cancer Surviv       Date:  2022-05-28       Impact factor: 4.442

Review 3.  Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions.

Authors:  Giovana R Onzi; Nathalia D'Agustini; Solange C Garcia; Silvia S Guterres; Paula R Pohlmann; Daniela D Rosa; Adriana R Pohlmann
Journal:  Drug Saf       Date:  2022-05-23       Impact factor: 5.606

Review 4.  Chemotherapy-induced cognitive impairment: focus on the intersection of oxidative stress and TNFα.

Authors:  Nicole G Rummel; Luksana Chaiswing; Subbarao Bondada; Daret K St Clair; D Allan Butterfield
Journal:  Cell Mol Life Sci       Date:  2021-08-23       Impact factor: 9.207

5.  Association of markers of tumor aggressivity and cognition in women with breast cancer before adjuvant treatment: The Thinking and Living with Cancer Study.

Authors:  Jeanne S Mandelblatt; Tim A Ahles; James C Root; Xingtao Zhou; Jaeil Ahn; Brent J Small; Wanting Zhai; Traci Bethea; Judith E Carroll; Harvey Jay Cohen; Asma Dilawari; Martine Extermann; Deena Graham; Claudine Isaacs; Paul B Jacobsen; Heather Jim; Brenna C McDonald; Zev M Nakamura; Sunita K Patel; Kelly Rentscher; Andrew J Saykin; Kathleen Van Dyk
Journal:  Breast Cancer Res Treat       Date:  2022-05-19       Impact factor: 4.624

Review 6.  Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events.

Authors:  Ana Dias-Carvalho; Mariana Ferreira; Rita Ferreira; Maria de Lourdes Bastos; Susana Isabel Sá; João Paulo Capela; Félix Carvalho; Vera Marisa Costa
Journal:  Arch Toxicol       Date:  2021-11-02       Impact factor: 5.153

7.  Manipulations of the gut microbiome alter chemotherapy-induced inflammation and behavioral side effects in female mice.

Authors:  C V Grant; B R Loman; M T Bailey; L M Pyter
Journal:  Brain Behav Immun       Date:  2021-04-22       Impact factor: 19.227

8.  Elevated Oxidative Stress and DNA Damage in Cortical Neurons of Chemotherapy Patients.

Authors:  Matthew Torre; Adwitia Dey; Jared K Woods; Mel B Feany
Journal:  J Neuropathol Exp Neurol       Date:  2021-08-11       Impact factor: 3.685

Review 9.  The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors.

Authors:  Elizabeth Cooper; Peter J Choi; William A Denny; Jiney Jose; Mike Dragunow; Thomas I-H Park
Journal:  Front Oncol       Date:  2021-06-01       Impact factor: 6.244

10.  Relationship between cognitive functioning and frailty in older breast cancer survivors.

Authors:  Tim A Ahles; Elizabeth Schofield; Yuelin Li; Elizabeth Ryan; James C Root; Sunita K Patel; Katrazyna McNeal; Alexandra Gaynor; Heidi Tan; Vani Katheria; Jessica Vazquez; Tiffany Traina; Arti Hurria
Journal:  J Geriatr Oncol       Date:  2021-08-05       Impact factor: 3.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.